Armata Pharmaceuticals (ARMP)
Develops bacteriophage cocktails for serious antibiotic-resistant bacterial infections.
Something off on this page? Send us feedback.
Develops pathogen-specific bacteriophage cocktails for hard-to-treat bacterial infections, with AP-SA02 and AP-PA02 as its main clinical programs. Research is funded through grants, awards, and capital while commercialization awaits clinical success, regulatory approval, and a partner or commercial buildout.
Develops fixed, pathogen-specific bacteriophage cocktails for antibiotic-resistant and difficult-to-treat bacterial infections. The pipeline centers on AP-SA02, an intravenous adjunct to antibiotics for complicated Staphylococcus aureus bacteremia, and AP-PA02, an inhaled candidate for chronic pulmonary Pseudomonas aeruginosa infections; AP-PA03 targets acute Pseudomonas pneumonia at the preclinical stage.
Combines phage discovery, host-range screening, cocktail design, process development, analytics, and cGMP manufacturing in Los Angeles. It has no approved products or commercial infrastructure, while clinical studies, manufacturing scale-up, and eventual commercialization depend on clinical evidence, regulatory approval, funding, and potential partners. Its core manufacturing operation is concentrated in Los Angeles.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $24.0M · Total debt $314.0M · Total assets $90.0M · Shareholders' equity −$231.2M
- Revenue
- $2.5M
- Operating income
- −$10.3M
- Net income
- $74.1M
No dividends on record.
| Institutions | 13.48% | 5.01M shares | |
|---|---|---|---|
| 54 holders · as of Jun 30, 2026 | |||
| Other | 86.52% | 32.17M shares | |
| remainder | |||
37.18M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Madison Asset Management, LLCInstitution | 5.67% | 2.11M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 1.51% | 559,986 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 1.31% | 487,968 | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 1.27% | 470,500 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.73% | 270,550 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Merck
Marketed IV bacteremia antibiotic and standard-of-care option.
- Gilead Sciences
Marketed inhaled antibiotic incumbent in CF Pseudomonas.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Armata Pharmaceuticals | $4.20 | −0.47% | $156.4M | — | — | 47.4 | +15.7% |
| Merck | $150.94 | +0.02% | $369.24B | 119.6 | 17.5 | 5.6 | +5.1% |
| Gilead Sciences | $152.73 | +0.04% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| Median | 119.6 | 17.1 | 5.8 | +7.6% |